Given the potential synthetic lethality relationship between ARID1A and EZH2 in cancer cells, the current evidence suggests that EZH2 could be a new target for synthetic lethality that can be targeted with drugs in cancers with ARID1A deficiency [5, 6, 16], as confirmed in this study. The gene discussed is EZH2; the disease is cancer.